Stockhub

Bio-Path Holdings, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

3 August 2022

  • curprev 10:0210:02, 3 August 2022‎ Chris talk contribs‎ 895 bytes +895‎ Created page with "Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Bio-Path_Holdings,_Inc.’